TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Controlled Randomised Trial of Ferric Carboxymaltose and Oral Iron to Treat Postpartum Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Woman within 48 h post partum~* Hemoglobin level equal or higher than 6.5 g/dl and equal or lower than 8.5 g/dl~* Able to read and understand the Norwegian language~* Signed informed consent~Exclusion Criteria:~* Anemia not attributable to iron deficiency~* Contraindications for any of the study drugs~* Treatment with drugs, dietary supplements or natural remedies containing iron~* Clinically significant condition which in the opinion of the investigator should disqualify the patient from the study~* Assessed as requiring blood transfusion(s)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Peroral iron - ferrous sulfate tablets (Type: ACTIVE_COMPARATOR): Peroral iron given as one tablet of ferrous sulfate 100 mg two times daily
- Ferric carboxymaltose (Type: ACTIVE_COMPARATOR): Intravenous infusion of Ferric Carboxymaltose (Ferinject), the given dose is adapted according to the individual patient's requirement. No other form of iron supplementation is given.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radiochemotherapy Followed by Adjuvant Chemotherapy Based on Gemcitabine in Uterine Cervical Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 70 years old~* Cervical uterine cancer (epidermoid or adenocarcinoma, stage:from IB\> or = 4 cm to IV, according to FIGO classification) histologically proven~* Measurable lesions,clinically and by MRI assessed~* PS-WHO \< or = 2 ou Karnofsky Index \>70 per cent~* Life expectancy \> 3 months~* Hematologic function: leukocytes \< or = 3 G/l, polynuclear neutrophil leukocytes \> or = 1.5 G/l, platelets \> or = 100 G/l, hemoglobin \> or = 10 g/dl~* Hepatic function: ASAT and ALAT \< 2.5 ULN~* Renal function: creatininemia \< 1.5 ULN, clearance \> 60 ml/min~* No prior chemotherapy or radiotherapy~* Contraception~* Written informed consent signed~Exclusion Criteria:~* Stage IB \< 4 cm or IVB~* Other histology than epidermoid or adenocarcinoma~* Distant metastases, including sus-clavicular adenopathy~* Contraindication to MRI~* Pregnant or lactating woman~* Auto-immune disease~* Peripheric neuropathy, autograft or homograft, psychiatric disease~* Prior cancer (except cutaneous basocellular carcinoma and uterine cervical carcinoma in situ)~* Active infection~* Other clinical trial with an experimental drug~* Known positive serology (HIV, HbC, HbS)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- patient with cervix cancer (Type: EXPERIMENTAL): will receive gemcitabine + cisplatin + radiotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Magseed as Localization Device for Biopsy Proven Metastatic Axillary Lymph Nodes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Women 18 years or older~2. Neoadjuvant chemotherapy planned prior to surgical excision~3. Scheduled for target axillary lymph node dissection including the localized lymph node and sentinel lymph node~Exclusion Criteria:~1. Pregnant or nursing women~2. Allergy to lidocaine or gadolinium~3. Contraindication to MRI (i.e. pacemaker)~4. Axillary Infection~5. Prior axillary radiation~6. Known allergy to bone wax, beeswax or propolis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Axillary Magseed (Type: EXPERIMENTAL): Single cohort of twenty women receiving neoadjuvant chemotherapy with breast cancer will have a Magseed inserted into a biopsy proven metastatic axillary lymph node for pre-surgical localization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: RETIC Trial: Reversal of Trauma Induced Coagulopathy Using Coagulation Factor Concentrates or Fresh Frozen Plasma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects =/\> 18 years and =/\< 80 years~2. Major trauma (ISS \> 15)~3. Clinical signs of ongoing bleeding or patients who are at risk for significant haemorrhage assessed and judged by the ED team in charge of patient~4. Presence of coagulopathy defined by ROTEM assays as follows,~   * Patients with concomitant decreased fibrinogen polymerisation (ROTEM® FibTEM A10 of \< 7 mm after 10 min)~  * Patients with concomitant decreased coagulation factor levels (ROTEM® ExTEM CT of \> 90 sec)~Exclusion Criteria:~1. Lethal injury~2. CPR on the scene,~3. Isolated brain injury, burn injury~4. Avalanche injury~5. Administration of FFP or coagulation factor concentrates before ED admission~6. Delayed (\> 6hours after trauma) admittance to ED~7. Known use of oral anticoagulants, or platelet aggregation inhibitors within 5 days before injury~8. Known history of severe allergic reaction to plasma products~9. Known history of congenital hemostasis disturbance, IgA or Protein C deficiency~10. Patients with a history of thromboembolic events or heparin induced thrombocytopenia (HIT) type 2 within the last year~11. Patients with a body weight \< 45kg and \> 150kg~12. Patients that are known to be pregnant~13. Jehova's Witness~14. Known participation in another clinical trial~15. Patient with known refusal of a participation in this clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Coagulation factor concentrates (Type: ACTIVE_COMPARATOR): None
- Fresh Frozen Plasma (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Peripheral Nerve Blocks in Pediatric Orthopedic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged between 6 yr and 17yr scheduled for ambulatory peripheral orthopedic surgery with moderate to severe postoperative pain.~* Surgery of moderate duration (\<2hr)~* Surgery associated with minimal blood loss or fluid shifts (\<10% total blood volume)~* ASA classification 1 or 2~* Parents able to understand follow up instructions and are able to reach at home by phone~Exclusion Criteria:~* Known allergy to local anesthetics~* Preexisting neuropathy with sensory or motor deficits~* Skin infection at site of needle placement~* Parents refusal for peripheral nerve blocks

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- General (Type: ACTIVE_COMPARATOR): General Anesthesia only
- Regional (Type: EXPERIMENTAL): General Anesthesia combined with regional block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Binet stage A CLL~* 2 or more risk factors:~* Unmutated IgVH locus (≥98% homology to germline sequence)~* CD38 expression (\>7%)~* Deletion of chromosome 11q22 (\>20% by FISH)~* Deletion of chromosome 17p13 (\>10% by FISH)~* Over 18 years old~* Capable to provide written informed consent~* ECOG performance status \< 2~* Life expectancy \> 2 years~* Must agree to not share lenalidomide with someone else~* Must agree not to donate blood whilst taking the study drug and for one week after discontinuation of treatment.~* Female subjects of childbearing potential and all male subjects must agree to comply with the stipulations of the pregnancy prevention plan.~Exclusion Criteria:~* Current or recent (within the last 1 month) participation in another clinical trial investigating the action of an investigational medicinal product for the treatment of CLL~* Pregnant or lactating~* Known positivity for human immunodeficiency virus (HIV) types 1 or 2~* Prior history of malignancies, other than CLL, unless the subject was treated with curative intent and has been free of the disease for ≥3 years. Exceptions include the following:~* Basal cell carcinoma of the skin~* Squamous cell carcinoma of the skin~* Carcinoma in situ of the cervix~* Carcinoma in situ of the breast~* Significantly abnormal renal or hepatic function (creatinine clearance \< 60ml/min, serum aspartate aminotransferase (AST) \> 3 x upper limit of normal (ULN), serum bilirubin \> 34μmol/l)~* Laboratory tumour lysis syndrome according to the Cairo-Bishop classification. Subjects may be enrolled when these abnormalities have been corrected.~* Peripheral neuropathy (grade ≥ 2)~* Previous treatment for CLL~* Previous treatment with Thalidomide or immunomodulatory derivative drugs (including Lenalidomide)~* Treatment with corticosteroids (for CLL or other indications) \< 28 days from study entry~* Evidence of Richter's transformation~* Unsupported absolute neutrophil count \< 1x109/l or platelet count \< 50x10\*9/l not due to CLL~* Active autoimmune haemolytic anaemia or thrombocytopenia~* Any other medical or psychological condition that in the view of the investigator would be likely to impact compliance with the protocol or interfere with trial treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide for early stage poor prognosis CLL (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Stellate Ganglion Blockade to Reduce Cardiac Anxiety and PTSD Symptoms in Cardiac Arrest Survivors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Age 18 years or older~2. Fluent in English or Spanish~3. A diagnosis of cardiac arrest (CA)~4. Admitted to the New York-Presbyterian Hospital~5. Elevated symptoms of psychological distress a. PCL-5 \> 32 with a minimum of 2 weeks after cardiac arrest~Exclusion criteria~1. A prior SGB treatment~2. Severe brain injury defined as Cerebral Performance Category Score ≥3, and/or significant aphasia, dysarthria, or cognitive impairment precluding ability to complete study questionnaires as determined by interviewer~3. Terminal non-cardiovascular illness (life expectancy \<1 year)~4. Severe mental illness requiring urgent psychiatric hospitalization~5. Alcohol or substance abuse that would impede ability to complete study~6. Unavailable for telephone and in-person follow-up~7. Allergy to amide local anesthetics (e.g., ropivacaine, bupivacaine)~8. Pre-existing Horner's syndrome~9. Pregnancy~10. Current anticoagulant use~11. History of a bleeding disorder~12. Infection or mass at injection site

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Stellate Ganglion Block + Psychoeducation (Type: EXPERIMENTAL): For the active SGB arm, 7 to 8 mL of ropivacaine, 0.5%, will be injected around and into the site of the ganglion once before the hospital discharge. They will also receive a 30 minutes session of psychoeducation by a health professional with experience working with CA patients.
- Normal saline injection + Psychoeducation (Type: PLACEBO_COMPARATOR): For the sham procedure, 1 to 2 mL of preservative-free normal saline will be injected into deep musculature in the neck. They will also receive a 30 minutes session of psychoeducation by a health professional with experience working with CA patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prospective and Monocentric Study of the Incidence of Venous Thromboembolic Disease (VTE) in Spinal Cord Injury (SCI) Patient Between 3 and 12 Months After SCI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years.~* Patients having paraplegia or tetraplegia from C2 levels and above S1~* Paraplegia and tetraplegia of traumatic or non progressive SCI from traumatic or medical origin (ischemic, post-surgical, myelitis, benign tumor)~* Informed consent signed.~* stabilized respiratory situation with absence of chronic hypoxemia (hypoxemia being characterized by PaO2 steady state \<7.33 kPa)~* Patient not amputated.~* Absence of heart failure with ejection fraction below 30%~* Lack of solid neoplasia or progressive lymphoid haemopathy for 5 years, or myeloproliferative disorders (including polycythemia and thrombocythemia).~* No personal history of VTE and / or thrombophilia before the injury.~Exclusion Criteria:~* Unstabilized respiratory situation with presence of chronic hypoxemia (hypoxemia being characterized by PaO2 steady state \<7.33 kPa)~* Amputated Patient.~* Patients with heart failure with ejection fraction below 30%~* Solid neoplasia or progressive lymphoid haemopathy for 5 years, or myeloproliferative disorders (including polycythemia and thrombocythemia).~* Personal history of VTE and / or thrombophilia before the injury.~* Can not to follow during the study period~* Pregnant women~* Patient Refusal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Spinal cord injury (SCI) patient (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Must be at least 18 years of age~* Have psoriasis or eczema on both sides of the body, with a pair of roughly symmetrical bilateral target lesions at least 1.5 cm in diameter~Exclusion Criteria~* Inability to understand the consent form and/or comply with the requirements of this study~* Use of moisturizers/emollients within 2 days of beginning study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): bilateral comparison
- 2 (Type: PLACEBO_COMPARATOR): bilateral comparison

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Male or female subjects aged 18 - 65 years of age, inclusive, in good general health as determined by medical evaluation Subject receives a negativeSARS-CoV-2 PCR test result at their screening or baseline visit~Exclusion Criteria:~Subjects will be excluded if they have clinically significant underlying conditions associated with high risk for severe COVID-19 infections as identified by the Centers for Disease Control and Prevention (CDC) (Appendix 2). These conditions include, but are not limited to: chronic obstructive pulmonary disease, diabetes mellitus (Type 1 and 2), obesity, hypertension, heart disease, and cerebrovascular disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Healthy uninfected/unexposed subjects to SARS-CoV-2
- Cohort 2 (Type: ACTIVE_COMPARATOR): Subjects who have recovered from SARS-CoV-2 infection
- Cohort 3 (Type: SHAM_COMPARATOR): Subjects who have received a complete SARS-CoV-2 vaccine course

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65~* 3-8 Migraine headaches/month~* Able to understand and comply with the study~Exclusion Criteria:~* Currently on migraine prophylaxis~* Currently on sleep medication \> 4days/month~* Currently on Fluvoxamine~* Untreated psychiatric or sleep disorders~* MRI abnormalities other than those attributable to migraine headaches~* Abnormalities on neurological exam other than known neurological disorders unassociated with migraine or sleep~* Known disorders of prolactin~* Bipolar disorder~* Hepatic disease~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): ramelteon 8 mg po qhs with sleep and migraine journal
- 2 (Type: PLACEBO_COMPARATOR): Placebo po qhs with sleep and migraine journal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, at least 18 years of age~* Histologically confirmed non-small cell lung cancer or malignancy pleural mesothelioma with at least one site of disease \> 1 cm by at least one type of standard imaging (e.g.~CT, chest x-ray, MRI)~* Recommended to start anti-PD1/PDL1 therapy.~* Obtaining pre-PD1/PDL1 therapy clinical re-staging \[18F\]FDG-PET/CT scan at the Hospital of the University of Pennsylvania.~* Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.~* Participants must be willing and able to comply with scheduled visits and imaging procedures in the opinion of the investigator or treating physician.~Exclusion Criteria~* Females who are pregnant or breast-feeding at the time of screening will not be eligible for this study. Female participants of child-bearing potential will have a urine pregnancy test at the time of the screening visit.~* Patients with only a single site of primary non-small cell lung cancer or malignancy pleural mesothelioma who have undergone or are recommended to undergo radiation therapy to that site will not be eligible, the inclusion of patients who may be undergoing radiation therapy to ancillary disease sites may be allowed to enter the study at the discretion of the PI if it is not felt to affect the ability to capture \[18F\]FDG information for at least one primary site of disease.~* Patients who have undergone cancer surgery removing a significant portion of active disease, in the opinion of an investigator, within 2 months prior to study enrollment will be excluded.~* Patients who have received prior immunotherapy.~* Patients with an active auto-immune disease (ie. Multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, vasculitis).~* Inability to tolerate imaging procedures in the opinion of the investigator or treating physician~* Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.~* Unwilling or unable to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues